The latest news for pharma industry insiders.

In this part of her video interview, Amanda Powers-Han, Chief Marketing Officer, Greater Than One and Pharmaceutical Executive Advisory Board Member explains how pharmaceutical companies can effectively navigate the evolving regulatory landscape and ensure that their marketing activities comply with ethical standards and industry best practices.

Dr. Sandra Lee is joining the educational program, which originally launched last year.

Results from the Phase II/III Vibrance-MG study found that patients with generalized myasthenia gravis who were treated with nipocalimab plus standard-of-care achieved sustained disease control.

Results from the Phase III Vivid-1 trial found that more Crohn disease patients treated with mirikizumab achieved histologic response at week 52 compared to ustekinumab.

Pharmaceutical companies are facing new guidelines, laws, and regulations requiring a reconsideration of how to prioritize, develop, commercialize, and ultimately, secure access to medicines.

The latest news for pharma industry insiders.

In this part of her video interview, Amanda Powers-Han, Chief Marketing Officer, Greater Than One and Pharmaceutical Executive Advisory Board Member discusses how CMOs can leverage artificial intelligence and other advanced analytics tools to extract meaningful insights and optimize marketing strategies.

Industry leaders gather to discuss different ways life sciences organizations can champion their environmentally-conscious younger employees while combatting still-entrenched public mistrust.

As part of the collaboration, Exelixis and Merck will evaluate zanzalintinib in combination with Keytruda for head and neck cancer.

As the overall industry pipeline of allogeneic T-cell therapies expands, the onus on manufacturers and their partners to adeptly manage the complex cryogenic logistics process intensifies.

Expanded indication of Bimzelx offers a prefilled syringe with a single 2 mL subcutaneous injection, improving upon the previous regimen of two 1 mL injections.

The latest news for pharma industry insiders.

In this part of her video interview, Amanda Powers-Han, Chief Marketing Officer, Greater Than One and Pharmaceutical Executive Advisory Board Member discusses how pharmaceutical companies can effectively balance personalized marketing efforts with maintaining data privacy and ensuring patient trust.

S-HiCon can reportedly achieve stable liquid formulation for over 200 mg/mL subcutaneous administration.

MedHub has been expanded to work with a wider variety of insurance plans.

The Big Pharma commercialization playbook doesn’t work for emerging life sciences companies bootstrapping their way up. Exploring three strategies that could be the ingredients of a winning formula for startups.

Rafaat Rahmani, president and founder of Lifescience Dynamics, grew up in abject poverty, but such hardships—and a later violent brush with racism—would ultimately end up fueling a determined and entrepreneurial path in the life sciences.

Acquisition of Longboard grants Lundbeck access to bexicaserin, 5-HT2C receptor agonist that has demonstrated promise in treating seizures associated with rare developmental epileptic encephalopathies.

Hympavzi is the first anti-tissue factor pathway inhibitor therapy to be approved in the United States for routine prophylaxis of bleeding in patients with hemophilia A or B without inhibitors.

Practical ways product teams can leverage the benefits of generative artificial intelligence as a strategic advantage in pharmaceutical and life sciences commercialization.

The latest news for pharma industry insiders.

Roaldi previously served as chief growth officer for UnitedHealthcare Community & State.

The challenges in obesity research are significant, but the opportunities for innovation are equally profound.

Respondents showed concern for cost increases and changes to benefits.